Tetsuro Yokokawa

Jun 1, 2024 | biorxiv.org | Sarah-Eve Lemay |Mónica S. Montesinos |Yann Grobs |Tetsuro Yokokawa

AbstractPulmonary arterial hypertension (PAH) is characterized by obliterative vascular remodeling of the small pulmonary arteries (PA) and progressive increase in pulmonary vascular resistance (PVR) leading to right ventricular (RV) failure. Although several drugs are approved for the treatment of PAH, mortality remains high. Accumulating evidence supports a pathological function of integrins in vessel remodeling, which are gaining renewed interest as drug targets.